EFFICACY OF THE LOW-DOSE COMBINED ORAL CONTRACEPTIVE CHLORMADINONE ACETATE/ETHINYLESTRADIOL: PHYSICAL AND EMOTIONAL BENEFITS https://www.contraceptionjournal.org/article/S0010-7824(09)00311-4/fulltext#secd9072256e571
This study investigated the effects of the low-dose combined oral contraceptive (COC) 2.0 mg chlormadinone acetate (CMA)/0.03 mg ethinylestradiol (EE) (Belara��, Balanca��) on cycle-related physical and emotional disorders in women ���25 years of age.
A prospective, non-interventional, observational study of 3772 women over six cycles was conducted in 303 office-based gynecological centers throughout Germany.
CMA/EE provided high contraceptive efficacy with a Pearl index of 0 (95% confidence interval=0.00���0.22) and was generally well tolerated, with no statistically significant weight changes during the observation period (p=.147). CMA/EE intake resulted in a statistically significant improvement in cycle-related physical and emotional symptoms, with a 67% overall reduction in sum score for number and intensity of cycle-related symptoms per patient.
The results of this study in women ���25 years of age support previous findings that 2.0 mg CMA/0.03 mg EE is an effective low-dose COC, with an excellent tolerability profile, with the additional benefits of significantly reducing both cycle-related physical and emotional symptoms (p���.001); women with the respective preexisting symptoms may, therefore, benefit from CMA/EE contraceptive treatment. Further research is warranted.